Core Viewpoint - Axon Enterprise, Inc. reported strong first-quarter 2025 results, with adjusted earnings and revenues exceeding consensus estimates, driven by robust demand for its products and services [1][2]. Financial Performance - Adjusted earnings per share for Q1 2025 were $1.41, surpassing the Zacks Consensus Estimate of $1.27, marking a 22.6% year-over-year increase [1]. - Total revenues reached $603.6 million, exceeding the consensus estimate of $589 million and reflecting a 31.3% year-over-year growth [2]. Business Segment Performance - **Connected Devices**: Revenues increased by 26% year over year to $340.9 million, driven by demand for TASER 10 devices and Axon Body 4 [3]. - **Software & Services**: Revenues rose 39% year over year to $262.7 million, attributed to a growing user base and increased adoption of premium features [4]. Cost and Margin Analysis - Cost of sales increased by 18.2% year over year to $237.9 million, while total operating expenses climbed 54.7% to $374.5 million [5]. - Adjusted gross margin improved slightly to 63.6% from 63.2% in the previous year [5]. Balance Sheet and Cash Flow - Cash and cash equivalents at the end of Q1 2025 were $1.09 billion, up from $454.8 million at the end of 2024 [6]. - The company generated net cash of $25.8 million from operating activities, compared to a cash outflow of $15.9 million in the previous year [6]. Free Cash Flow - Adjusted free cash flow for the first three months of 2025 was $932 million, a significant increase from $32.1 million in the prior year [7]. Outlook for 2025 - Axon expects revenues to be between $2.60 billion and $2.70 billion, indicating approximately 27% year-over-year growth at the midpoint [8]. - Adjusted EBITDA is projected to be in the range of $650 million to $675 million, with an adjusted EBITDA margin of about 25% [8]. - Capital expenditures are anticipated to be between $160 million and $180 million, focusing on R&D and capacity expansion [9].

分组1 - Axon Enterprise reported quarterly earnings of $1.41 per share, exceeding the Zacks Consensus Estimate of $1.27 per share, and up from $1.15 per share a year ago, representing an earnings surprise of 11.02% [1] - The company achieved revenues of $603.63 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.47%, and an increase from $460.74 million year-over-year [2] - Over the last four quarters, Axon has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has gained approximately 1.2% since the beginning of the year, while the S&P 500 has declined by 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is $1.43, with expected revenues of $636.96 million, and for the current fiscal year, the EPS estimate is $6.11 on revenues of $2.62 billion [7] - The Aerospace - Defense Equipment industry, to which Axon belongs, is currently ranked in the top 14% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Financial Data and Key Metrics Changes - First quarter revenue reached $604 million, representing a 31% year-over-year increase, marking the thirteenth consecutive quarter of over 25% growth [24] - Adjusted EBITDA margin was reported at 25.7%, with annual recurring revenue (ARR) of $1.1 billion, reflecting a 34% year-over-year increase [24][30] - Adjusted gross margin improved to 63.6%, up 40 basis points year-over-year, primarily due to a shift towards software [27] Business Line Data and Key Metrics Changes - Software and services revenue increased by 39% year-over-year to $263 million, driven by strong demand for digital evidence management and premium add-ons [26] - Connected devices revenue grew by 26% year-over-year to $341 million, fueled by sales of TASER 10 devices and cartridges [27] - TASER 10 orders are pacing at twice the adoption rate of TASER 7, indicating strong market acceptance [20] Market Data and Key Metrics Changes - International bookings showed strong performance, with demand noted in Australia, Latin America, Canada, Asia, the UK, and Europe [20] - Emerging verticals, including corrections and justice, experienced triple-digit growth, while enterprise solutions are building a strong pipeline [21] Company Strategy and Development Direction - The company is focused on building an ecosystem with partners to enhance public safety through technology, including the introduction of the Axon Assistant and AI-powered solutions [6][8] - The strategic shift to connected devices and software and services segments reflects the company's increasing product diversification [25] - The company aims to maintain a strong focus on R&D investments while managing supply chain challenges due to tariffs [28][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong pipeline and bookings for the remainder of 2025, anticipating record annual bookings growth [19][30] - The leadership acknowledged potential macroeconomic challenges but noted minimal impact on core markets, particularly in US state and local sectors [46] - The company is optimistic about the federal market, particularly with new budget allocations for advanced security technologies [84] Other Important Information - The company has updated its segment reporting to better align with its diversified product offerings [25] - Management highlighted the importance of ethical considerations in technology deployment, particularly regarding privacy and public safety [54] Q&A Session Summary Question: What drove the strong ARR growth in Q1? - Management indicated that the strong ARR growth was primarily driven by robust bookings from Q4 and an increase in new users and premium subscriptions [37] Question: What factors are contributing to international growth? - The company noted improved focus on international markets and better execution from the sales team as key drivers of growth [40] Question: Are there any macroeconomic concerns affecting demand? - Management reported virtually no headwinds in US state and local markets, although federal opportunities are somewhat stalled pending budget clarity [46] Question: How is the company addressing the fixed ALPR market? - The company is leveraging its existing imaging technology to provide best-in-class fixed ALPR solutions, with a dedicated sales team for this product line [102] Question: What is the outlook for federal contracts? - Management expressed optimism about federal contracts, particularly in border security and advanced technologies, while noting that FUSIS is progressing towards FedRAMP certification [92][93]

Financial Data and Key Metrics Changes - First quarter revenue reached $604 million, representing a 31% year-over-year increase, marking the thirteenth consecutive quarter of over 25% growth [26][27] - Adjusted EBITDA margin was reported at 25.7%, with annual recurring revenue (ARR) of $1.1 billion, reflecting a 34% year-over-year increase [26][27] - Adjusted gross margin improved to 63.6%, up 40 basis points year-over-year, primarily due to a shift towards software [28] Business Line Data and Key Metrics Changes - Software and services revenue increased by 39% year-over-year to $263 million, driven by strong demand for digital evidence management and premium add-ons [27] - Connected devices revenue grew by 26% year-over-year to $341 million, fueled by sales of TASER 10 devices and cartridges [28] Market Data and Key Metrics Changes - International bookings showed strong momentum, with demand noted in Australia, Latin America, Canada, Asia, the UK, and Europe, contributing to the top 10 international deals in the quarter [22] - Emerging verticals, including corrections and justice, experienced triple-digit growth, while enterprise markets are building a strong pipeline [23] Company Strategy and Development Direction - The company is focused on building an ecosystem for public safety, integrating various technologies and partnerships to enhance community safety [12][14] - The new AI Era Plan aims to provide predictable pricing and access to innovative AI solutions, enhancing the company's product offerings [8][12] - The company is committed to maintaining its headquarters in Arizona, overcoming legislative hurdles to support long-term growth [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong pipeline and bookings for the remainder of 2025, anticipating record annual bookings [21][31] - The company is prepared to navigate macroeconomic challenges, with minimal headwinds reported in key markets [47] - Future guidance for 2025 includes revenue expectations in the range of $2.6 to $2.7 billion, reflecting a 27% growth rate at the midpoint [31] Other Important Information - The company has updated its segment reporting to better align with its diversified product offerings, now categorizing them into connected devices and software and services [26] - Tariff impacts are expected to affect adjusted EBITDA margin guidance by approximately 50 basis points for the full year, but no price increases are planned for customers [30] Q&A Session Summary Question: What drove the strong ARR growth in Q1? - Management indicated that the strong ARR growth was primarily driven by robust bookings from Q4, with contributions from both new users and existing customers upgrading to premium plans [38][39] Question: What factors are contributing to international growth? - The company noted improved focus on international markets, enhanced execution, and a diverse product adoption strategy as key drivers of international growth [40][41] Question: Are there any macroeconomic concerns affecting demand? - Management reported virtually no headwinds in US state and local markets, although federal opportunities are somewhat stalled pending budget clarity [47][49] Question: How is the company addressing the fixed ALPR market? - The company is excited about entering the fixed ALPR market, leveraging existing relationships and technology to provide competitive offerings [102] Question: What is the outlook for federal opportunities? - The company is focusing on border security technologies and real-time video solutions, anticipating significant demand in these areas [83][84]

[Special Note Regarding Forward-Looking Statements](index=4&type=section&id=Special%20Note%20Regarding%20Forward-Looking%20Statements) This section highlights that the report contains forward-looking statements subject to risks and uncertainties, with no obligation for public updates unless legally required - The report contains forward-looking statements subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, indicating future expectations, beliefs, intentions, and strategies[9](index=9&type=chunk) - Achievement of future results is subject to risks, uncertainties, and potentially inaccurate assumptions, with actual results potentially differing materially from past or anticipated results[10](index=10&type=chunk) - The company does not undertake to publicly update forward-looking statements, except as required by law, and advises consulting further disclosures in Form 8-K, 10-Q, and 10-K reports[11](index=11&type=chunk) [PART I - FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) This section provides Axon Enterprise, Inc.'s unaudited consolidated financial statements and management's discussion and analysis for the quarter ended March 31, 2025 [Item 1. Financial Statements (unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents Axon Enterprise, Inc.'s unaudited consolidated financial statements for the quarter ended March 31, 2025, including balance sheets, statements of operations, stockholders' equity, cash flows, and accompanying condensed notes [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) This section provides a snapshot of Axon's financial position, detailing assets, liabilities, and stockholders' equity as of March 31, 2025, and December 31, 2024 | (in thousands) | March 31, 2025 | December 31, 2024 | | :--------------------------------- | :------------- | :---------------- | | **ASSETS** | | | | Cash and cash equivalents | $1,092,938 | $454,844 | | Short-term investments | 1,099,230 | 333,235 | | Total current assets | 3,776,589 | 2,297,481 | | Total assets | $6,083,159 | $4,474,588 | | **LIABILITIES AND STOCKHOLDERS' EQUITY** | | | | Current portion of notes payable, net | 278,915 | 680,289 | | Total current liabilities | 1,336,622 | 1,677,875 | | Long-term notes payable, net | 1,727,797 | — | | Total liabilities | 3,527,306 | 2,146,923 | | Total stockholders' equity | 2,555,853 | 2,327,665 | | Total liabilities and stockholders' equity | $6,083,159 | $4,474,588 | - Total assets increased by **$1.61 billion** from December 31, 2024, to March 31, 2025, primarily driven by increases in cash and cash equivalents and short-term investments[15](index=15&type=chunk) - Total liabilities increased significantly, mainly due to the reclassification of long-term notes payable and the issuance of new Senior Notes, while current portion of notes payable decreased[15](index=15&type=chunk) [Consolidated Statements of Operations and Comprehensive Income](index=8&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income) This section outlines Axon's financial performance, presenting net sales, operating expenses, net income, and earnings per share for the three months ended March 31, 2025 and 2024 | (in thousands, except per share data) | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 (As Restated) | | :------------------------------------ | :-------------------------------- | :---------------------------------------------- | | Net sales | $603,633 | $459,871 | | Cost of sales | 237,894 | 201,243 | | Gross margin | 365,739 | 258,628 | | Total operating expenses | 374,532 | 242,172 | | (Loss) income from operations | (8,793) | 16,456 | | Net income | $87,980 | $133,352 | | Basic EPS | $1.14 | $1.77 | | Diluted EPS | $1.08 | $1.73 | | Comprehensive income | $88,214 | $132,445 | - Net sales increased by **31.3% YoY to $603.63 million**, driven by growth in both product and service sales[17](index=17&type=chunk) - The company reported an **operating loss of $8.79 million** for Q1 2025, a significant decrease from an operating income of $16.46 million in Q1 2024, primarily due to increased operating expenses[17](index=17&type=chunk) - Net income decreased to **$87.98 million** in Q1 2025 from $133.35 million in Q1 2024, impacting both basic and diluted EPS[17](index=17&type=chunk) [Consolidated Statements of Stockholders' Equity](index=9&type=section&id=Consolidated%20Statements%20of%20Stockholders%27%20Equity) This section details changes in Axon's stockholders' equity, including common stock, additional paid-in capital, and retained earnings, for the period ended March 31, 2025 | (in thousands, except share data) | Balance, Dec 31, 2024 | Issuance of common stock under employee plans, net | Stock-based compensation | Induced conversion of convertible debt | Tax effect of partial repurchase of convertible debt | Net income | Other comprehensive income, net | Balance, Mar 31, 2025 | | :-------------------------------- | :-------------------- | :------------------------------------------------- | :----------------------- | :------------------------------------- | :--------------------------------------------------- | :--------- | :------------------------------ | :-------------------- | | Common Stock Shares | 76,619,331 | 190,558 | — | 1,038,259 | — | — | — | 77,848,148 | | Additional Paid-in Capital | $1,689,781 | $(5,035) | $140,239 | $20,819 | $(16,049) | — | — | $1,829,755 | | Retained Earnings | $812,014 | — | — | — | — | $87,980 | — | $899,994 | | Total Stockholders' Equity | $2,327,665 | $(5,035) | $140,239 | $20,819 | $(16,049) | $87,980 | $234 | $2,555,853 | - Total stockholders' equity increased from **$2.33 billion** at December 31, 2024, to **$2.56 billion** at March 31, 2025[19](index=19&type=chunk) - Key drivers of the change include **$140.24 million** in stock-based compensation, **$87.98 million** in net income, and **$20.82 million** from the induced conversion of convertible debt[19](index=19&type=chunk) [Consolidated Statements of Cash Flows](index=10&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) This section presents Axon's cash inflows and outflows from operating, investing, and financing activities for the three months ended March 31, 2025 and 2024 | (in thousands) | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 (As Restated) | | :------------------------------------ | :-------------------------------- | :---------------------------------------------- | | Net cash provided by (used in) operating activities | $25,794 | $(15,938) | | Net cash used in investing activities | $(702,217) | $(174,044) | | Net cash provided by (used in) financing activities | $1,313,226 | $(2,710) | | Net increase (decrease) in cash and cash equivalents | $637,995 | $(194,670) | | Cash and cash equivalents, end of period | $1,092,938 | $403,870 | - Net cash provided by operating activities significantly improved to **$25.79 million** in Q1 2025 from a use of **$(15.94) million** in Q1 2024[22](index=22&type=chunk) - Net cash used in investing activities increased substantially to **$(702.22) million** in Q1 2025, primarily due to higher purchases of investments[22](index=22&type=chunk) - Net cash provided by financing activities surged to **$1.31 billion** in Q1 2025, driven by the issuance of **$1.75 billion** in Senior Notes, partially offset by payments for induced conversion of convertible debt[22](index=22&type=chunk) [Condensed Notes to Consolidated Financial Statements](index=12&type=section&id=Condensed%20Notes%20to%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures supporting the consolidated financial statements, covering significant accounting policies, segment information, and other financial notes [Note 1 - Organization and Summary of Significant Accounting Policies](index=12&type=section&id=Note%201%20-%20Organization%20and%20Summary%20of%20Significant%20Accounting%20Policies) This note describes Axon's business, mission, restatement of prior financial statements, segment realignment, and significant accounting policies including warranty reserves and debt accounting - Axon Enterprise, Inc. is a provider of public safety technology solutions, with a mission to protect life in service of promoting peace, justice, and strong institutions[23](index=23&type=chunk) - The company restated previously issued financial statements for March 31, 2024, due to material errors related to the balance sheet presentation of convertible senior notes and principal vs. agent accounting of certain reseller arrangements[26](index=26&type=chunk)[27](index=27&type=chunk)[30](index=30&type=chunk) - Effective Q1 2025, Axon realigned its business into two reportable segments: 'Connected Devices' (hardware solutions like CEDs, body cameras, drones) and 'Software & Services' (cloud-based software solutions like Axon Evidence, RMS)[35](index=35&type=chunk) Warranty Reserve Changes (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :----------------------- | :-------------------------------- | :-------------------------------- | | Balance, beginning of period | $8,284 | $7,374 | | Utilization of reserve | (1,701) | (2,207) | | Warranty expense | 3,779 | 1,119 | | Balance, end of period | $10,362 | $6,286 | - Axon early adopted ASU 2024-04, Debt (Topic 470): Debt with Conversion and Other Options, in March 2025 to clarify accounting for induced conversion or debt extinguishment[55](index=55&type=chunk) [Note 2 - Revenues](index=20&type=section&id=Note%202%20-%20Revenues) This note details Axon's revenue breakdown by segment, product/service offering, and geography, along with information on remaining performance obligations Revenues by Segment and Product/Service Offering (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------- | :-------------------------------- | :-------------------------------- | | **Connected Devices** | | | | TASER | $195,495 | $164,599 | | Personal Sensors | 88,405 | 68,000 | | Platform Solutions | 56,996 | 37,825 | | **Software & Services** | | | | Software and Services | 262,737 | 189,447 | | **Total** | $603,633 | $459,871 | Revenues by Geography (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------- | :-------------------------------- | :-------------------------------- | | United States | $529,383 (88%) | $391,541 (85%) | | Other countries | $74,250 (12%) | $68,330 (15%) | | Total | $603,633 (100%) | $459,871 (100%) | - Remaining performance obligations totaled approximately **$7.7 billion** as of March 31, 2025, with **20%-25%** expected to be recognized over the next 12 months[59](index=59&type=chunk) [Note 3 - Cash, Cash Equivalents and Investments](index=22&type=section&id=Note%203%20-%20Cash%2C%20Cash%20Equivalents%20and%20Investments) This note provides a detailed breakdown of Axon's cash, cash equivalents, marketable securities, and available-for-sale debt investments, including unrealized gains and losses Cash, Cash Equivalents, Marketable Securities and Available-for-Sale Debt Investments (in thousands) as of March 31, 2025 | | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | Cash and Cash Equivalents | Marketable Securities | Short-Term Investments | | :-------------------- | :------------- | :--------------------- | :---------------------- | :--------- | :------------------------ | :-------------------- | :--------------------- | | Cash | $95,886 | — | — | $95,886 | $95,886 | — | — | | Money market funds | 558,249 | — | — | 558,249 | 558,249 | — | — | | U.S. Treasury bills | 205,498 | 23 | (9) | 205,512 | 82,350 | — | 123,162 | | Marketable securities | 90,000 | 84,870 | — | 174,870 | — | 174,870 | — | | Term deposits | 742,415 | — | — | 742,415 | 157,415 | — | 585,000 | | Corporate bonds | 346,150 | 32 | (173) | 346,009 | 88,066 | — | 257,943 | | Total | $2,282,318 | $84,926 | $(206) | $2,367,038 | $1,092,938 | $174,870 | $1,099,230 | - As of March 31, 2025, the company held **$515.4 million** of available-for-sale debt investments with unrealized losses, none of which have been in a continuous unrealized loss position for 12 months or longer[60](index=60&type=chunk) - An unrealized loss of **$23.4 million** on marketable securities was recorded for the three months ended March 31, 2025, compared to an unrealized gain of **$21.8 million** in the prior year[61](index=61&type=chunk) [Note 4 - Expected Credit Losses](index=25&type=section&id=Note%204%20-%20Expected%20Credit%20Losses) This note presents the roll-forward of the allowance for expected credit losses and its breakdown by receivable type for Axon's financial assets Allowance for Expected Credit Losses Roll-Forward (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :------------------------------------ | :-------------------------------- | :-------------------------------- | | Balance, beginning of period | $5,609 | $3,966 | | Provision for expected credit losses | 2,955 | 217 | | Amounts written off charged against the allowance | (487) | (353) | | Balance, end of period | $8,077 | $3,844 | Allowance for Expected Credit Losses by Receivable Type (in thousands) | | March 31, 2025 | December 31, 2024 | | :------------------------------------ | :------------- | :---------------- | | Accounts receivable and notes receivable, current | $3,204 | $3,322 | | Contract assets, net | 4,825 | 2,239 | | Long-term notes receivable, net of current portion | 48 | 48 | | Total allowance | $8,077 | $5,609 | [Note 5 - Inventory](index=25&type=section&id=Note%205%20-%20Inventory) This note details the composition of Axon's inventory, including raw materials, work-in-process, and finished goods, as of March 31, 2025, and December 31, 2024 Inventory Composition (in thousands) | | March 31, 2025 | December 31, 2024 | | :-------------- | :------------- | :---------------- | | Raw materials | $108,087 | $86,840 | | Work-in-process | 8,387 | 6,230 | | Finished goods | 163,195 | 172,246 | | Total inventory | $279,669 | $265,316 | - Total inventory increased by **$14.35 million** from December 31, 2024, to March 31, 2025, primarily driven by an increase in raw materials and work-in-process[66](index=66&type=chunk) [Note 6 – Goodwill and Intangible Assets](index=25&type=section&id=Note%206%20%E2%80%93%20Goodwill%20and%20Intangible%20Assets) This note outlines changes in Axon's goodwill by segment and provides a breakdown of intangible assets, including amortization expense Changes in Goodwill (in thousands) | | Connected Devices | Software and Services | Total | | :------------------------------ | :---------------- | :-------------------- | :---- | | Balance, beginning of period | $46,674 | $710,164 | $756,838 | | Purchase accounting adjustments | (160) | (2,535) | (2,695) | | Foreign currency translation adjustments | 119 | 1,620 | 1,739 | | Balance, end of period | $46,633 | $709,249 | $755,882 | Intangible Assets (in thousands) as of March 31, 2025 | | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | | :-------------------------- | :-------------------- | :----------------------- | :------------------ | | Developed technology | $133,572 | $(26,299) | $107,273 | | Customer relationships | 33,482 | (5,728) | 27,754 | | In-process research and development | 25,750 | — | 25,750 | | Total intangible assets | $207,114 | $(38,280) | $168,834 | - Amortization expense for intangible assets was **$6.6 million** for the three months ended March 31, 2025, an increase from **$3.0 million** in the prior year[69](index=69&type=chunk) [Note 7 - Strategic Investments](index=26&type=section&id=Note%207%20-%20Strategic%20Investments) This note details Axon's strategic investment activities, including acquisitions, sales, and the recognition of gains and losses on these investments - During Q1 2025, Axon acquired additional equity interests in an existing strategic investee for **$203.4 million**[74](index=74&type=chunk) - A gain of **$167.4 million** was recognized related to an observable price change of a separate existing strategic investee, and interests were sold for **$340.7 million** in cash consideration, realizing **$273.5 million** in previously unrealized gains[75](index=75&type=chunk) Strategic Investments Carrying Value (in thousands) as of March 31, 2025 | | Strategic Investments | Warrants | Call options | Total | | :------------------------- | :-------------------- | :------- | :----------- | :---- | | Non-marketable equity securities | $388,390 | $4,368 | $11,600 | $404,358 | | Non-marketable debt securities | 9,335 | — | — | 9,335 | | Total strategic investments | $397,725 | $4,368 | $11,600 | $413,693 | Gains and Losses on Strategic Investments (in thousands) for Three Months Ended March 31, 2025 | | Strategic Investments | Warrants | Call options | Total | | :------------------------------------ | :-------------------- | :------- | :----------- | :---- | | Realized gains (losses), net | $273,478 | — | — | $273,478 | | Reversal of cumulative unrealized gains, net | (136,982) | — | — | (136,982) | | Unrealized gains on strategic investments still held | 30,825 | — | — | 30,825 | | Gains (losses) on strategic investments, net | $167,321 | — | — | $167,321 | [Note 8 - Variable Interest Entities](index=30&type=section&id=Note%208%20-%20Variable%20Interest%20Entities) This note discusses Axon's variable interests in unconsolidated non-public entities, primarily for strategic partnerships in public safety technology solutions - Axon holds variable interests in unconsolidated non-public VIEs, primarily to create strategic partnerships in public safety technology solutions[81](index=81&type=chunk) Carrying Value of Variable Interest - Assets (in thousands) | | March 31, 2025 | December 31, 2024 | | :-------------------------------- | :------------- | :---------------- | | Carrying value of variable interest - assets | $25,922 | $25,171 | [Note 9 - Accrued Liabilities](index=31&type=section&id=Note%209%20-%20Accrued%20Liabilities) This note provides a breakdown of Axon's accrued liabilities, including income tax payable, salaries, commissions, and warranty expense, as of March 31, 2025, and December 31, 2024 Accrued Liabilities (in thousands) | | March 31, 2025 | December 31, 2024 | | :-------------------------- | :------------- | :---------------- | | Accrued income tax payable | $82,602 | $17,091 | | Accrued salaries and benefits | 24,044 | 25,233 | | Accrued commissions | 23,226 | 88,237 | | Accrued cloud hosting fees | 18,425 | 10,673 | | Accrued bonus | 16,889 | 59,780 | | Accrued warranty expense | 10,362 | 8,284 | | Accrued interest | 6,423 | 134 | | Total accrued liabilities | $266,604 | $279,193 | - Accrued income tax payable significantly increased from **$17.09 million** to **$82.60 million**, while accrued commissions and bonus decreased[84](index=84&type=chunk) [Note 10 – Notes Payable, Net](index=31&type=section&id=Note%2010%20%E2%80%93%20Notes%20Payable%2C%20Net) This note details Axon's notes payable, including the issuance of new Senior Notes and the repurchase of 2027 Notes, along with related interest expenses Notes Payable, Net (in thousands) | | March 31, 2025 | December 31, 2024 | | :------------------------------------ | :------------- | :---------------- | | 2030 Senior Notes | $1,000,000 | — | | 2033 Senior Notes | 750,000 | — | | 2027 Notes | 282,547 | 690,000 | | Total principal | 2,032,547 | 690,000 | | Total carrying amount of notes payable, net | 2,006,712 | 680,289 | | Long-term notes payable, net | $1,727,797 | — | - In March 2025, Axon issued **$1.0 billion** of 2030 Senior Notes (6.125% interest) and **$750.0 million** of 2033 Senior Notes (6.250% interest), with combined net proceeds of approximately **$1.73 billion**[86](index=86&type=chunk)[87](index=87&type=chunk) - Axon repurchased approximately **$407.5 million** aggregate principal amount of 2027 Notes through induced conversions, resulting in an expense of **$28.7 million** and leaving **$282.5 million** outstanding[96](index=96&type=chunk) Interest Expense Related to Notes (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------- | :-------------------------------- | :-------------------------------- | | Senior Notes interest expense | $6,178 | — | | 2027 Notes interest expense | $1,527 | $1,645 | [Note 11 - Income Taxes](index=37&type=section&id=Note%2011%20-%20Income%20Taxes) This note explains Axon's effective tax rate, its drivers, and changes in deferred tax assets for the three months ended March 31, 2025 and 2024 Effective Tax Rate | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------- | :-------------------------------- | :-------------------------------- | | Effective tax rate | 18.8% | 19.6% | - The decrease in effective tax rate was primarily due to higher R&D tax credits and discrete benefits from stock-based compensation, partially offset by executive compensation limitations and increased uncertain tax positions[104](index=104&type=chunk)[105](index=105&type=chunk) - Deferred tax assets increased from **$301.9 million** to **$333.3 million**, mainly due to stock-based compensation expense and capitalization of R&D costs, partially offset by reversal of assets from 2027 Notes repurchase[106](index=106&type=chunk) [Note 12 - Stockholders' Equity](index=37&type=section&id=Note%2012%20-%20Stockholders%27%20Equity) This note details changes in Axon's stockholders' equity, including information on stock plans, restricted stock unit activity, and stock-based compensation expense - Shareholders approved the 2024 eXponential Stock Plan (XSP) with **4.5 million shares** reserved for XSUs, and a 2024 CEO Performance Award of **679,102 XSUs**, both with stock price, operational, and service vesting conditions[108](index=108&type=chunk)[109](index=109&type=chunk)[110](index=110&type=chunk) Restricted Stock Unit (RSU) Activity (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------- | :-------------------------------- | :-------------------------------- | | Units outstanding, beginning of year | 1,684 | 1,615 | | Granted | 15 | 478 | | Released | (186) | (174) | | Units outstanding, end of period | 1,486 | 1,877 | | Aggregate intrinsic value at quarter end | $781,511 | $587,321 | Stock-based Compensation Expense (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :------------------------------------ | :-------------------------------- | :-------------------------------- | | Cost of product and service sales | $12,887 | $29,595 | | Selling, general and administrative expenses | 71,347 | 23,155 | | Research and development expenses | 56,005 | 22,365 | | Total stock-based compensation expense | $140,239 | $75,115 | [Note 13 - Line of Credit](index=43&type=section&id=Note%2013%20-%20Line%20of%20Credit) This note describes the amendment to Axon's revolving credit facility, including the increased principal amount, extended maturity, and available borrowing capacity - In March 2025, the revolving credit facility was amended, increasing the aggregate principal amount by **$100.0 million** to **$300.0 million** and extending the maturity date to March 11, 2030[122](index=122&type=chunk) - As of March 31, 2025, no amounts were drawn under the Credit Agreement, with **$8.7 million** in outstanding letters of credit and **$291.3 million** in available borrowing[123](index=123&type=chunk) - The company is in compliance with the net leverage ratio and consolidated interest coverage ratio covenants under the Credit Agreement[124](index=124&type=chunk) [Note 14 - Commitments and Contingencies](index=43&type=section&id=Note%2014%20-%20Commitments%20and%20Contingencies) This note outlines Axon's legal proceedings, including product liability, antitrust, and patent infringement lawsuits, as well as outstanding letters of credit and surety bonds - Axon is a defendant in product liability lawsuits alleging wrongful death or personal injury related to TASER CED use, which the company aggressively defends[125](index=125&type=chunk)[126](index=126&type=chunk) - Two antitrust lawsuits are pending in New Jersey and Arizona, based on FTC allegations regarding Axon's 2018 acquisition of Vievu LLC, which Axon denies[127](index=127&type=chunk) - A patent infringement suit by Airspace Systems, Inc. against Dedrone Holdings, Inc. (and Axon after acquisition) is pending, involving drone technology, with litigation stayed until September 15, 2025[129](index=129&type=chunk) - As of March 31, 2025, Axon had **$8.7 million** in outstanding letters of credit under its credit facility and **$21.6 million** in outstanding surety bonds[132](index=132&type=chunk) [Note 15 – Accumulated Other Comprehensive Income (Loss)](index=45&type=section&id=Note%2015%20%E2%80%93%20Accumulated%20Other%20Comprehensive%20Income%20(Loss)) This note details changes in Axon's accumulated other comprehensive income (loss), including unrealized losses on available-for-sale investments and foreign currency translation adjustments Changes in Accumulated Other Comprehensive Income (Loss) (in thousands) | | Unrealized Losses on Available-for-Sale Investments | Foreign Currency Translation | Total | | :-------------------------- | :---------------------------------------- | :--------------------------- | :---- | | Balance, December 31, 2024 | $(30) | $(18,154) | $(18,184) | | Other comprehensive (loss) income | (124) | 358 | 234 | | Balance, March 31, 2025 | $(154) | $(17,796) | $(17,950) | - Accumulated other comprehensive loss slightly decreased from **$(18.18) million** to **$(17.95) million**, primarily due to positive foreign currency translation adjustments[133](index=133&type=chunk) [Note 16 - Segment Data](index=47&type=section&id=Note%2016%20-%20Segment%20Data) This note presents Axon's financial results by its two reportable segments, Connected Devices and Software & Services, including net sales, cost of sales, and adjusted gross margin - Effective Q1 2025, financial results are reported in two segments: Connected Devices and Software & Services, with prior period data recast for comparability[135](index=135&type=chunk) Segment Financial Results (in thousands) for Three Months Ended March 31, 2025 | | Connected Devices | Software and Services | Total | | :------------------ | :---------------- | :-------------------- | :---- | | Net sales | $340,896 | $262,737 | $603,633 | | Cost of sales | 170,181 | 67,713 | 237,894 | | Adjusted gross margin | $180,135 | $204,061 | $384,196 | Adjusted Gross Margin Percentage | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------- | :-------------------------------- | :-------------------------------- | | Connected Devices | 52.8% | 54.1% | | Software and Services | 77.7% | 76.1% | | Total Adjusted Gross Margin | 63.6% | 63.2% | [Note 17 – Business Combinations](index=48&type=section&id=Note%2017%20%E2%80%93%20Business%20Combinations) This note describes Axon's business combinations, including the acquisitions of Fusus and Dedrone, and the recognition and reallocation of goodwill and intangible assets - On January 31, 2024, Axon acquired the remaining **79.7%** interest in Fusus for approximately **$241.3 million**, recognizing **$249.9 million** of goodwill and **$72.9 million** of identifiable intangible assets[138](index=138&type=chunk) - On October 1, 2024, Axon acquired the remaining **79.8%** interest in Dedrone for approximately **$391.1 million**, recognizing **$448.4 million** of goodwill and **$100.5 million** of identifiable intangible assets[140](index=140&type=chunk)[142](index=142&type=chunk) - Goodwill recognized from both Fusus and Dedrone acquisitions has been reallocated to the new Connected Devices and Software & Services segments[139](index=139&type=chunk)[143](index=143&type=chunk) [Note 18 - Restatement of Prior Period Financial Statements](index=48&type=section&id=Note%2018%20-%20Restatement%20of%20Prior%20Period%20Financial%20Statements) This note explains the restatement of prior period financial statements to correct immaterial errors related to principal vs. agent accounting and the classification of 2027 Notes - Prior period financial statements were restated to correct immaterial errors related to principal vs. agent accounting under ASC 606 and the balance sheet classification of 2027 Notes[144](index=144&type=chunk) Impact of Restatement on Consolidated Statement of Operations and Comprehensive Income (in thousands) for Three Months Ended March 31, 2024 | | As Reported | Adjustments | As Restated | | :------------------------------------ | :---------- | :---------- | :---------- | | Net sales from products | $272,048 | $(1,624) | $270,424 | | Net sales from services | 188,688 | 759 | 189,447 | | Net sales | 460,736 | (865) | 459,871 | | Gross margin | 260,046 | (1,418) | 258,628 | | Net income | $133,218 | $134 | $133,352 | - The restatement had no impact on disclosed basic and diluted income per common and common equivalent shares for the three months ended March 31, 2024[146](index=146&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=52&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on Axon's financial performance for the three months ended March 31, 2025, discussing key financial results, segment realignment, non-GAAP measures, liquidity, and critical accounting estimates [Overview](index=52&type=section&id=Overview) This overview highlights Axon's mission, business segment realignment, and key financial performance metrics for Q1 2025, including revenues, operating loss, and gross margin - Axon's mission is to protect life in public safety, aiming to cut gun-related deaths between police and the public in the U.S. in half by 2033[151](index=151&type=chunk) - The company realigned its business into two reportable segments: Connected Devices and Software & Services, effective Q1 2025, to enhance transparency between hardware and software offerings[152](index=152&type=chunk) Key Financial Highlights (in millions) | Metric | Q1 2025 | Q1 2024 | Change (%) | | :-------------------- | :------ | :------ | :--------- | | Revenues | $603.6 | $459.9 | 31.3% | | (Loss) Income from operations | $(8.8) | $16.5 | -153.3% | | Gross margin | $365.7 | $258.6 | 41.4% | | Gross margin % | 60.6% | 56.2% | 4.4 pp | | Net income | $88.0 | $133.4 | -34.0% | [Results of Operations](index=53&type=section&id=Results%20of%20Operations) This section analyzes Axon's net sales by product and service, segment performance, operating expenses, and other income for the three months ended March 31, 2025 and 2024 Net Sales Breakdown (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :-------------------------- | :-------------------------------- | :-------------------------------- | | Net sales from products | $340,896 (56.5%) | $270,424 (58.8%) | | Net sales from services | $262,737 (43.5%) | $189,447 (41.2%) | | Total net sales | $603,633 (100.0%) | $459,871 (100.0%) | - Connected Devices segment net sales increased **26.1% YoY to $340.9 million**, driven by higher TASER 10 volume, AB4 body camera adoption, and growth in virtual reality training and counter-drone equipment[156](index=156&type=chunk) - Software and Services segment net sales increased **38.7% YoY to $262.7 million**, primarily due to increased users and adoption of premium add-on features[157](index=157&type=chunk) Operating Expenses (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :------------------------------------ | :-------------------------------- | :-------------------------------- | | Selling, general and administrative | $223,509 | $151,075 | | Research and development | 151,023 | 91,097 | | Total operating expenses | $374,532 | $242,172 | - SG&A expenses increased by **$72.4 million (47.9%) YoY**, mainly due to higher stock-based compensation (**$48.2 million increase**) and increased headcount and wages[160](index=160&type=chunk)[161](index=161&type=chunk)[162](index=162&type=chunk) - R&D expenses increased by **$59.9 million (65.8%) YoY**, primarily driven by a **$33.6 million increase** in stock-based compensation and higher headcount and wages[163](index=163&type=chunk)[164](index=164&type=chunk) - Other income, net, decreased to **$114.4 million** from **$139.1 million**, primarily due to a noncash unrealized loss on marketable securities and debt inducement expense, partially offset by realized and unrealized gains on strategic investments[166](index=166&type=chunk) [Non-GAAP Measures](index=57&type=section&id=Non-GAAP%20Measures) This section presents Axon's non-GAAP financial measures, including EBITDA, Adjusted EBITDA, and Adjusted Gross Margin, to provide insights into core operating performance - Axon uses non-GAAP financial measures like EBITDA, Adjusted EBITDA, and Adjusted Gross Margin to provide a clearer view of core operating results, excluding items such as stock-based compensation and amortization of acquired intangibles[170](index=170&type=chunk)[172](index=172&type=chunk) EBITDA and Adjusted EBITDA Reconciliation (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :------------------------------------ | :-------------------------------- | :-------------------------------- | | Net income | $87,980 | $133,352 | | EBITDA | $124,803 | $167,086 | | Stock-based compensation expense | 140,239 | 75,115 | | Unrealized and realized gains on strategic investments and marketable securities, net | (143,921) | (97,419) | | Debt inducement expense | 28,666 | — | | Adjusted EBITDA | $155,170 | $109,071 | Adjusted Gross Margin Reconciliation (in thousands) | | Connected Devices (Q1 2025) | Software and Services (Q1 2025) | Total (Q1 2025) | Connected Devices (Q1 2024) | Software and Services (Q1 2024) | Total (Q1 2024) | | :-------------------------- | :-------------------------- | :-------------------------- | :-------------- | :-------------------------- | :-------------------------- | :-------------- | | Gross margin | $170,715 | $195,024 | $365,739 | $118,264 | $140,364 | $258,628 | | Stock-based compensation expense | 7,476 | 5,411 | 12,887 | 27,827 | 1,768 | 29,595 | | Amortization of acquired intangible assets | 3,626 | 1,337 | 4,963 | 325 | 1,963 | 2,288 | | Adjusted gross margin | $180,135 | $204,061 | $384,196 | $146,416 | $144,095 | $290,511 | | Adjusted gross margin % | 52.8% | 77.7% | 63.6% | 54.1% | 76.1% | 63.2% | [Liquidity and Capital Resources](index=61&type=section&id=Liquidity%20and%20Capital%20Resources) This section analyzes Axon's liquidity and capital resources, including cash and investments, credit facility availability, and a summary of cash flows from operating, investing, and financing activities Cash and Investments Summary (in thousands) | | March 31, 2025 | December 31, 2024 | Dollar Change | | :-------------------------- | :------------- | :---------------- | :------------ | | Cash and cash equivalents | $1,092,938 | $454,844 | $638,094 | | Available-for-sale investments | 1,099,230 | 333,235 | 765,995 | | Total | $2,192,168 | $788,079 | $1,404,089 | - Cash and cash equivalents increased by **$638.1 million**, and available-for-sale investments increased by **$766.0 million**, primarily due to investment activity following the issuance of Senior Notes[174](index=174&type=chunk) - The Credit Agreement provides a **$300.0 million** revolving credit facility, with **$291.3 million** available for borrowing as of March 31, 2025, and no amounts drawn[175](index=175&type=chunk) Cash Flows Summary (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | Dollar Change | | :-------------------------- | :-------------------------------- | :-------------------------------- | :------------ | | Operating activities | $25,794 | $(15,938) | $41,732 | | Investing activities | $(702,217) | $(174,044) | $(528,173) | | Financing activities | $1,313,226 | $(2,710) | $1,315,936 | - Net cash provided by operating activities improved by **$41.7 million**, driven by changes in net income, stock-based compensation, and working capital[180](index=180&type=chunk) - Net cash provided by financing activities increased by **$1.3 billion**, primarily from the issuance of **$1.75 billion** in Senior Notes, partially offset by payments for induced conversion of 2027 Notes[182](index=182&type=chunk) [Critical Accounting Estimates](index=63&type=section&id=Critical%20Accounting%20Estimates) This section confirms that Axon's critical accounting estimates have not significantly changed for the three months ended March 31, 2025, as discussed in its amended 2024 Annual Report - The company's critical accounting estimates, as discussed in its amended 2024 Annual Report on Form 10-K/A, have not undergone significant changes for the three months ended March 31, 2025[184](index=184&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=64&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section assesses Axon's exposure to market risks, specifically interest rate risk and exchange rate risk, and outlines strategies for managing these exposures - A hypothetical **100 basis point increase** in interest rates would result in a **$2.1 million** decline in the fair market value of the investment portfolio as of March 31, 2025[186](index=186&type=chunk) - The **$300.0 million** revolving credit facility bears interest at SOFR plus **1.25% to 1.75%**, exposing future borrowings to interest rate fluctuations[187](index=187&type=chunk) - The majority of international sales are transacted in foreign currencies, subjecting results to exchange rate fluctuations, which can impact product costs and competitiveness[188](index=188&type=chunk) - Axon has not engaged in currency hedging activities to date but may consider foreign currency forward and option contracts in the future[189](index=189&type=chunk) [Item 4. Controls and Procedures](index=64&type=section&id=Item%204.%20Controls%20and%20Procedures) This section addresses the effectiveness of Axon's disclosure controls and procedures, noting material weaknesses in internal control over financial reporting and ongoing remediation efforts - The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures were **not effective** as of March 31, 2025, due to unremediated material weaknesses in internal control over financial reporting[190](index=190&type=chunk) - Management is implementing remediation plans for identified material weaknesses, which cannot be considered remediated until controls operate effectively for a sufficient period and are tested[191](index=191&type=chunk) - There have been no changes in internal control over financial reporting during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting[193](index=193&type=chunk) [PART II - OTHER INFORMATION](index=66&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) This section covers additional information not included in the financial statements, such as legal proceedings, risk factors, equity sales, defaults, mine safety, and exhibits [Item 1. Legal Proceedings](index=66&type=section&id=Item%201.%20Legal%20Proceedings) This section incorporates by reference the discussion of legal proceedings from Note 14 to the consolidated financial statements - The discussion of legal proceedings is incorporated by reference from Note 14 to the consolidated financial statements[195](index=195&type=chunk) [Item 1A. Risk Factors](index=66&type=section&id=Item%201A.%20Risk%20Factors) This section provides a comprehensive overview of the principal risks that could materially adversely affect Axon's business, financial condition, results of operations, and cash flows, categorized into strategic, operational, financial, legal and compliance, and indebtedness-related risks [Risk Factor Summary](index=66&type=section&id=Risk%20Factor%20Summary) This summary outlines key risk categories including Strategic, Operational, Financial, Legal and Compliance, and risks related to the company's indebtedness - The summary outlines key risk categories including Strategic, Operational, Financial, and Legal and Compliance Risks[197](index=197&type=chunk)[198](index=198&type=chunk)[201](index=201&type=chunk)[202](index=202&type=chunk) - Risks related to the company's indebtedness are also highlighted as a principal risk factor[204](index=204&type=chunk) [Strategic Risks](index=69&type=section&id=Strategic%20Risks) This section details risks related to product acceptance, dependence on CED sales, new product development, technological change, negative publicity, acquisitions, growth management, and key personnel - Substantial dependence on acceptance of products and services by law enforcement agencies globally; declining purchases would materially adversely affect business[199](index=199&type=chunk)[206](index=206&type=chunk)[209](index=209&type=chunk) - Dependence on sales of Conducted Energy Devices (CEDs); failure to maintain widespread acceptance would diminish growth prospects[210](index=210&type=chunk) - Inability to successfully design, introduce, sell, and deploy new products or features in a timely and cost-effective manner could adversely affect business and financial results[212](index=212&type=chunk)[216](index=216&type=chunk) - Risks associated with rapid technological change and new competing products, including AI and machine learning, could render existing products obsolete[217](index=217&type=chunk) - Negative publicity, whether merited or not, could damage the Axon brand and adversely impact sales and operating results[220](index=220&type=chunk)[221](index=221&type=chunk)[224](index=224&type=chunk) - Acquisitions or investments in other products, technologies, or businesses could disrupt operations, dilute shareholder value, and adversely affect operating results due to integration difficulties and unforeseen costs[225](index=225&type=chunk)[226](index=226&type=chunk)[228](index=228&type=chunk)[229](index=229&type=chunk) - Failure to successfully manage rapid growth or plan for future growth could strain management, operational, and financial resources[230](index=230&type=chunk)[231](index=231&type=chunk) - High dependence on executive officers, particularly CEO Patrick W. Smith; loss of key personnel could adversely impact new product development and business execution[232](index=232&type=chunk)[233](index=233&type=chunk)[234](index=234&type=chunk) [Operational Risks](index=77&type=section&id=Operational%20Risks) This section covers risks associated with supply chain, economic conditions, manufacturing capacity, product development delays, sales cycles, security breaches, catastrophic events, AI deployment, cloud service defects, product defects, international operations, personnel retention, and regulatory compliance - Unavailability of materials or higher costs from domestic and international suppliers, including single-source components, could adversely affect financial results and production capacity[235](index=235&type=chunk)[236](index=236&type=chunk)[237](index=237&type=chunk)[238](index=238&type=chunk)[239](index=239&type=chunk) - Material adverse developments in domestic and global economic conditions (e.g., conflicts, inflation, interest rates) could negatively impact revenue and operating results, especially due to pressure on law enforcement budgets[240](index=240&type=chunk) - Future success depends on the ability to manage growth and increase manufacturing production capacity to meet increased demand, which may incur significant costs and delays[241](index=241&type=chunk) - Delays in product development schedules for CEDs, devices, sensors, and software could adversely affect revenues and cash flows, as new products require long development and testing periods[242](index=242&type=chunk)[243](index=243&type=chunk) - Lengthy sales cycles, particularly with government entities, require significant resource expenditure before sales are realized, with no guarantee of revenue[244](index=244&type=chunk) - Security breaches of products, services, or third-party providers could lead to unauthorized data access, undermine confidence, disrupt business, and result in significant legal and financial exposure[245](index=245&type=chunk)[246](index=246&type=chunk)[247](index=247&type=chunk)[248](index=248&type=chunk)[249](index=249&type=chunk) - Catastrophic events (e.g., natural disasters, cyber attacks, public health crises) could disrupt systems, delay sales, and harm business prospects and financial condition[250](index=250&type=chunk)[251](index=251&type=chunk)[252](index=252&type=chunk)[254](index=254&type=chunk) - Uncertainty in the development, deployment, and use of AI in products and services could lead to defects, errors, biased outcomes, and reputational damage, compounded by evolving legal and regulatory landscapes[255](index=255&type=chunk)[256](index=256&type=chunk)[257](index=257&type=chunk)[258](index=258&type=chunk)[259](index=259&type=chunk)[260](index=260&type=chunk)[261](index=261&type=chunk) - Defects or disruptions in cloud services, relying on third-party providers, could impact demand, lead to substantial liability, and damage reputation, especially for public safety customers[262](index=262&type=chunk)[263](index=263&type=chunk) - Defects in products, including software errors, could reduce demand, result in product recalls, and lead to loss of sales, delayed market acceptance, and reputational harm[264](index=264&type=chunk)[265](index=265&type=chunk) - International operations expose the company to additional risks, including foreign ownership restrictions, stringent exchange controls, trade regulations, and differing labor laws[266](index=266&type=chunk)[267](index=267&type=chunk)[268](index=268&type=chunk)[269](index=269&type=chunk) - Dependence on attracting and retaining key management, sales, and technical personnel; failure to do so could adversely impact business execution and growth[270](index=270&type=chunk)[271](index=271&type=chunk)[272](index=272&type=chunk)[274](index=274&type=chunk)[275](index=275&type=chunk) - Failure to comply with federal, state, or local regulations applicable to the TASER 10 CED, including ATF rules and firearm laws, could result in governmental actions, litigation, or harm to business[276](index=276&type=chunk)[277](index=277&type=chunk)[278](index=278&type=chunk) [Financial Risks](index=91&type=section&id=Financial%20Risks) This section addresses financial risks including delayed cash collections from subscriptions, gross margin fluctuations, revenue recognition for SaaS, government budgetary constraints, bidding processes, cash concentration, stock transactions, currency fluctuations, tax rate changes, quarterly volatility, and investment impairments - An increasing percentage of revenue from subscription billing arrangements may result in delayed cash collections and increased customer credit risk on receivables and contract assets[283](index=283&type=chunk)[284](index=284&type=chunk) - Gross margin depends on factors like product mix, cost structure, and acquisitions, which could cause significant fluctuations and impact stock price[285](index=285&type=chunk)[287](index=287&type=chunk) - Revenue for SaaS products is recognized over multi-year contract terms, delaying the reflection of new business in operating results[288](index=288&type=chunk) - Most end-user customers are government agencies subject to budgetary and political constraints, which may delay sales, result in cancellations, or lead to non-renewal of contracts[289](index=289&type=chunk)[290](index=290&type=chunk)[291](index=291&type=chunk)[292](index=292&type=chunk) - The open bidding process for government contracts introduces uncertainty in securing future awards and favorable terms[293](index=293&type=chunk)[295](index=295&type=chunk)[296](index=296&type=chunk) - Holding the majority of cash balances at three depository institutions, some uninsured, exposes the company to potential losses if these institutions fail[297](index=297&type=chunk)[298](index=298&type=chunk) - Stock transactions, including stock-based compensation and equity issuances for acquisitions, may have a material, unpredictable impact on operating results and result in dilution to existing shareholders[299](index=299&type=chunk)[300](index=300&type=chunk)[301](index=301&type=chunk) - Financial performance is subject to risks associated with changes in the value of the U.S. dollar versus local currencies, impacting international pricing, sales, and earnings[302](index=302&type=chunk)[303](index=303&type=chunk)[304](index=304&type=chunk) - Unanticipated changes in the effective tax rate and additional tax liabilities, influenced by statutory rates, geographic earnings, and regulatory changes, could adversely affect operating results and financial condition[305](index=305&type=chunk)[306](index=306&type=chunk)[307](index=307&type=chunk)[308](index=308&type=chunk)[309](index=309&type=chunk) - Revenue and operating results may fluctuate unexpectedly quarter-to-quarter due to various factors, impacting stock price[310](index=310&type=chunk)[312](index=312&type=chunk) - Profitability could suffer from declines in fair value or impairment of investments, including strategic investments, and could fluctuate with increases in fair value[313](index=313&type=chunk) [Legal and Compliance Risks](index=99&type=section&id=Legal%20and%20Compliance%20Risks) This section outlines legal and compliance risks such as product liability claims, other litigation, intellectual property infringement, inability to protect IP, open-source software use, evolving regulations, procurement laws, governance expectations, and forum provisions - The company may face personal injury, wrongful death, product liability, and other liability claims related to the use of its CED products, which could harm its reputation and financial condition[314](index=314&type=chunk)[315](index=315&type=chunk)[316](index=316&type=chunk)[317](index=317&type=chunk) - Other litigation, government inquiries, and regulatory actions, including intellectual property and antitrust cases, may subject the company to significant costs, judgments, and divert management attention[318](index=318&type=chunk)[319](index=319&type=chunk) - Exposure to intellectual property infringement claims from third parties, including non-practicing entities, could incur substantial litigation costs, damages, and inhibit technology use[320](index=320&type=chunk)[321](index=321&type=chunk) - Inability to protect intellectual property (patents, trademarks, copyrights, trade secrets) could decrease brand value, lead to loss of competitive market advantage, and incur costly prosecution[322](index=322&type=chunk)[323](index=323&type=chunk)[324](index=324&type=chunk)[326](index=326&type=chunk) - Inability to enforce patent rights internationally may limit the ability to prevent competitors from using product features in foreign jurisdictions[327](index=327&type=chunk) - The use of open-source software in products, services, and technologies may expose the company to additional risks, including disclosure of proprietary source code[328](index=328&type=chunk) - A variety of new and existing laws and/or interpretations (privacy, data protection, content, competition, etc.) could materially and adversely affect the business, increasing compliance costs and potentially leading to liabilities[329](index=329&type=chunk)[330](index=330&type=chunk)[331](index=331&type=chunk) - Uncertainties with complex U.S. federal, state, local, and foreign procurement laws and regulations could cause the company to incur costs and adversely affect business[332](index=332&type=chunk)[333](index=333&type=chunk) - Evolving corporate governance and public disclosure regulations and expectations, including ESG matters, could increase expenses, divert management time, and adversely affect reputation[334](index=334&type=chunk)[335](index=335&type=chunk)[336](index=336&type=chunk)[338](index=338&type=chunk) - Exclusive forum provisions in amended and restated bylaws could increase costs or limit shareholders' ability to bring claims in preferred judicial forums[339](index=339&type=chunk)[340](index=340&type=chunk) [Risks Related to our Indebtedness](index=107&type=section&id=Risks%20Related%20to%20our%20Indebtedness) This section details risks associated with Axon's debt obligations, including cash resource requirements, conditional conversion features, shareholder dilution, hedge and warrant transactions, counterparty risk, and restrictive covenants - Fulfilling debt obligations requires significant cash resources, which may exceed available cash flow, potentially requiring asset sales, debt restructuring, or additional equity capital[341](index=341&type=chunk) - The conditional conversion features of the 2027 Notes may adversely affect financial condition and operating results by requiring cash settlement and potentially classifying debt as a current liability[342](index=342&type=chunk)[343](index=343&type=chunk) - Conversion of the 2027 Notes may dilute shareholder ownership and could depress the price of common stock, especially if settled with shares[344](index=344&type=chunk) - The 2027 Note Hedge and Warrant transactions may impact the value of the 2027 Notes and common stock, with potential dilutive effects from Warrants and market fluctuations from counterparty hedging activities[345](index=345&type=chunk)[347](index=347&type=chunk)[348](index=348&type=chunk)[349](index=349&type=chunk) - Exposure to counterparty risk with respect to the 2027 Note Hedge transactions, as counterparties are financial institutions and obligations are unsecured, could lead to adverse tax consequences and greater dilution[350](index=350&type=chunk)[351](index=351&type=chunk)[352](index=352&type=chunk) - Indebtedness contains restrictive covenants that could limit operational flexibility, affecting business expansion, strategic transactions, and financing, thereby adversely affecting common stock value[353](index=353&type=chunk)[354](index=354&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=109&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section states that there were no unregistered sales of equity securities or use of proceeds during the reporting period - No unregistered sales of equity securities or use of proceeds occurred during the period[355](index=355&type=chunk) [Item 3. Defaults Upon Senior Securities](index=109&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section confirms that there were no defaults upon senior securities during the reporting period - No defaults upon senior securities occurred during the period[356](index=356&type=chunk) [Item 4. Mine Safety Disclosures](index=109&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section indicates that there were no mine safety disclosures required for the reporting period - No mine safety disclosures were reported[356](index=356&type=chunk) [Item 5. Other Information](index=110&type=section&id=Item%205.%20Other%20Information) This section details Rule 10b5-1(c) trading plans adopted by certain directors or officers during the three months ended March 31, 2025 Rule 10b5-1(c) Trading Plans Adopted by Directors/Officers | Name and Title | Adoption Date | Expiration Date | Aggregate Number of Securities to be Sold | | :------------------------------------------ | :------------ | :-------------- | :---------------------------------------- | | Jeffrey Kunins, Chief Product Officer and Chief Technology Officer | March 10, 2025 | December 15, 2025 | 15,977 | | Jennifer Mak, Chief Accounting Officer | March 14, 2025 | February 27, 2026 | 8,768 | - No other Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements were entered into, modified, or terminated by directors or officers during the period[358](index=358&type=chunk) [Item 6. Exhibits](index=110&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed as part of the Quarterly Report on Form 10-Q, including corporate documents, debt indentures, employment agreements, and certifications - Key exhibits include Amended and Restated Certificate of Incorporation, Bylaws, Indentures for 2030 and 2033 Senior Notes, an Executive Employment Agreement, and certifications from the Principal Executive and Financial Officers[359](index=359&type=chunk) [SIGNATURES](index=113&type=section&id=SIGNATURES) This section confirms the official signing of the report by Axon's Chief Executive Officer and Chief Operating Officer/Chief Financial Officer - The report is duly signed on May 7, 2025, by Patrick Smith, Chief Executive Officer, and Brittany Bagley, Chief Operating Officer and Chief Financial Officer[362](index=362&type=chunk)[364](index=364&type=chunk)

CONTACT: Investor Relations Axon Enterprise, Inc. IR@axon.com Axon reports Q1 2025 revenue of $604 million, up 31% year over year Fellow shareholders, Axon delivered a strong start to 2025, achieving record quarterly revenue while maintaining healthy margins and reinforcing our foundation for long-term growth through continued product innovation and a strengthened balance sheet. First quarter revenue reached $604 million, representing 31% year-over-year growth and marking our 13th consecutive quarter of gro ...

Company Overview - Axon's mission is to protect life by building the technology ecosystem for public safety[7] - The company estimates a total addressable market of $129 billion[9, 69] - Axon aims to cut gun-related deaths between police and the public by 50% by 2033[10] Financial Performance - Axon achieved $2.1 billion in annual revenue in 2024[32] - The company's annual recurring revenue reached $1.1 billion[34, 127] - Future contracted bookings totaled $9.9 billion as of Q1 2025[34, 125] - The annual Adjusted EBITDA margin was 25% in 2024[34] - Net revenue retention was 123% in 2024[34, 126] Growth Strategy - Axon is expanding its reach globally and connecting with customers across the world[79] - The company is upgrading antiquated technologies and optimizing products to help prioritize existing resources[81] - Axon is innovating and improving existing products, with public safety adoption typically gradual and durable[72]

Core Insights - Axon Enterprise (AXON) is expected to report quarterly earnings of $1.27 per share, a 10.4% increase year-over-year, with revenues projected at $589.09 million, reflecting a 27.9% year-over-year growth [1] Earnings Estimates - The consensus EPS estimate has been revised 9.1% higher in the last 30 days, indicating a collective reevaluation by analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3] Revenue Forecasts - Analysts predict 'Net Sales- Software and Sensors' will reach $371.61 million, a 31.8% increase from the previous year [5] - 'Revenue- TASER' is expected to be $218.76 million, indicating a 22.4% year-over-year change [5] - 'Net Sales- Services- Software and Sensors' is forecasted at $248.29 million, reflecting a 40.7% increase year-over-year [5] Product Sales Estimates - 'Net Sales- Products- Software and Sensors' is projected to be $123.31 million, a 16.9% increase year-over-year [6] - 'Net Sales- Products- TASER' is expected to reach $200.30 million, indicating a 20.3% year-over-year change [6] - 'Net Sales- Services- TASER' is forecasted at $15.35 million, reflecting a 25.6% increase from the previous year [6] Additional Sales Insights - The consensus estimate for 'Net Sales- Products' stands at $323.84 million, a 19% increase year-over-year [7] - 'Net Sales- Services' is expected to be $264.40 million, indicating a 40.1% year-over-year change [7] - 'Net Sales- Products- TASER- Other' is projected to reach $12.14 million, reflecting a significant 288.2% increase year-over-year [8] Annual Recurring Revenue - Analysts estimate 'Annual recurring revenue' to be $1,051.50 million, compared to $825 million from the previous year [8] Stock Performance - Over the past month, Axon shares have recorded a return of +15.1%, outperforming the Zacks S&P 500 composite, which changed by -0.5% [9]

Company Performance - Axon Enterprise (AXON) closed at $621.10, with a daily gain of +1.27%, outperforming the S&P 500's gain of 0.63% [1] - Over the past month, Axon shares increased by 9.83%, significantly surpassing the Aerospace sector's gain of 2.14% and the S&P 500's loss of 0.7% [1] Upcoming Earnings - The upcoming earnings report for Axon Enterprise is scheduled for May 7, 2025, with an expected EPS of $1.27, indicating a 10.43% increase year-over-year [2] - Revenue is projected at $589.09 million, reflecting a 27.86% rise compared to the same quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are estimated at $6.11 per share and revenue at $2.62 billion, representing increases of +2.86% and +25.7% respectively from the prior year [3] - Recent revisions to analyst forecasts are crucial as they indicate changing business trends, with positive revisions suggesting analyst optimism about the company's profitability [3] Zacks Rank and Stock Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), indicates that Axon Enterprise currently holds a Zacks Rank of 2 (Buy) [5] - Over the past month, the Zacks Consensus EPS estimate for Axon has increased by 4.52% [5] Valuation Metrics - Axon Enterprise has a Forward P/E ratio of 100.34, which is significantly higher than the industry average of 30.91, suggesting that the company is trading at a premium [6] - The PEG ratio for Axon is 3.61, compared to the industry average PEG ratio of 2.36, indicating a higher valuation relative to projected earnings growth [7] Industry Context - The Aerospace - Defense Equipment industry, part of the Aerospace sector, has a Zacks Industry Rank of 34, placing it in the top 14% of over 250 industries [7] - The Zacks Industry Rank measures the strength of industry groups, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [8]

Core Insights - The recent passing of a continuing resolution (CR) by Congress highlights evolving priorities and potential investment opportunities, particularly in defense spending [1][2] Defense Industry - Defense spending is a key area of focus, with an additional $9 billion secured for the Department of Defense (DoD) through the latest CR, emphasizing modernization and new technologies [2] - Lockheed Martin is identified as a leading defense stock, currently priced at $476.44, with a 12-month price forecast of $544.79, indicating a 14.35% upside potential [4] - Northrop Grumman, with a current price of $480.81, has a 12-month price forecast of $545.31, reflecting a 13.42% upside, supported by a record backlog exceeding $94 billion [8][9] - Axon Enterprise, a provider of technology solutions for law enforcement, has a current price of $596.91 and a 12-month price forecast of $626.45, showing a 4.95% upside [10] Company Performance - Lockheed Martin's stock is down over 15% from its October 2024 highs despite a record revenue year in 2024 and solid momentum in 2025 [4][5] - Northrop Grumman's revenue topped $41 billion in 2024, and the company was awarded over $50 billion in new contracts, contributing to long-term stability [8][9] - Axon Enterprise has seen a significant price increase of over 95% in the last 12 months, indicating strong growth potential despite being considered pricey by traditional valuation measures [11]